New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
The company is to test its KLK2-targeting pasritamig in a late-line setting.
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.
But first it will need to identify the optimal dose in first-line small-cell lung cancer.
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
